Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy

Circulation

Volumn 100, Issue 9, 1999, Pages 933-939

  Barbaro, Giuseppe ^a,d   Di Lorenzo, Gabriella ^a   Soldini, Maurizio ^a   Giancaspro, Giuseppe ^a   Grisorio, Benvenuto ^b   Pellicelli, Adriano ^c   Barbarini, Giorgio ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GENERAL HOSPITAL   (Italy)

^c 2nd Division of Infectious Diseases   (Italy)

^d NONE

Author keywords

AIDS; Cardiomyopathy; Hormones; Nitric oxide synthase; Viruses

Indexed keywords

NITRIC OXIDE SYNTHASE;

ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART DILATATION; HEART MUSCLE BIOPSY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS;

EID: 0033621142     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.9.933     Document Type: Article

References (32)

1. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G, and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. AIDS Res Hum Retroviruses. 1998;14:1071-1077.
2. Grody W, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol. 1990;66:203-206.
3. Herskowitz A, Tzyy-Choou W, Willoughby SB, Vlahov D, Ansari AA, Beshorner WE, Baughman KL. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol. 1994; 24:1025-1032.
4. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G for the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV positive patients. N Engl J Med. 1998;339:1093-1099.
5. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients. N Engl J Med. 1998;339:1153-1155.
6. Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest. 1996;97:1837-1843.
7. Freeman GL, Colston JT, Zabalgoitia M, Chandrasekar B. Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol. 1998;274:249-258.
8. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiorayopathy. Lancet. 1996;347:1151-1155.
9. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathology and pharmacology. Pharmacol Rev. 1991;43:109-142.
10. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
11. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol Chem Hoppe-Seyler. 1995;376:327-343.
12. Center for Disease Control, and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
13. Himelman RB, Chung WS, Chernoff DN, Schiller NB, Hollander H. Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1989;13: 1030-1036.
14. Caves PK, Stinson EB, Billingham ME, Shumway NE. Percutaneous transvenous endomyocardial biopsy in human heart recipients: experience with a new technique. Ann Thorac Surg. 1973;16:325-336.
15. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987;18: 619-624.
16. Beschorner WE, Baughman KL, Turnicky RP, Hutchins GM, Rowe SA, Kavanaugh-McHugh AL, Suresch DL, Herskowitz A. HIV-associated myocarditis: pathology and immunopathology. Am J Pathol. 1990;137: 1365-1371.
17. Woods GL, Gutierrez Y. Diagnostic Pathology of Infectious Diseases. Philadelphia, Pa: Lea & Febiger; 1993.
18. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford, UK: Blackwell Scientific; 1994.
19. Mason JW. Endomyocardial biopsy and the causes of dilated cardiomyopathy. J Am Coll Cardiol. 1994;23:591-592.
20. Kasten-Sportes C, Weinstein C. Molecular mechanisms of HIV cardiovascular disease. In: Lipshultz SE, ed. Cardiology in AIDS. New York, NY: Chapman & Hall: 1998:265-282.
21. Matsumori A. Cytokines in myocarditis and cardiomyopathy. Curr Opin Cardiol. 1996;11:302-309.
22. Yokohama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effect of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92: 2303-2312.
23. Torre-Armione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
24. Habib FM, Dutka D, Crossman D, Oakley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet. 1994;344:371-373.
25. Ungureanu-Longrois D, Balligand JL, Simmons WW, Okada I, Kobzik L, Lowenstein CJ, Kunkel SL, Michel T, Kelly RA, Smith TW. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res. 1995;77:494-502.
26. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998; 274:577-595.
27. Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity. 1999;10:21-28.
28. Zaragoza C, Ocampo C, Saura M, Leppo M, Wei XQ, Quick R, Moncada S, Liew FY, Lowenstein CJ. The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc Natl Acad Sci U S A. 1998;95:2469-2474.
29. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-209.
30. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system: effects of thrombin inhibitors. J Clin Invest. 1994;93:2073-2083.
31. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest. 1995;95:677-685.
32. Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation. 1995;92:2220-2225.